Forbes J M & Co. LLP lifted its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 111,682 shares of the company’s stock after acquiring an additional 149 shares during the quarter. Johnson & Johnson accounts for 2.2% of Forbes J M & Co. LLP’s portfolio, making the stock its 17th largest position. Forbes J M & Co. LLP’s holdings in Johnson & Johnson were worth $19,105,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. American Money Management LLC grew its position in shares of Johnson & Johnson by 1.1% in the 4th quarter. American Money Management LLC now owns 33,834 shares of the company’s stock worth $5,788,000 after buying an additional 380 shares during the last quarter. Summit Trail Advisors LLC grew its position in Johnson & Johnson by 2.8% during the 4th quarter. Summit Trail Advisors LLC now owns 4,486 shares of the company’s stock worth $767,000 after purchasing an additional 124 shares during the last quarter. Northeast Financial Consultants Inc grew its position in Johnson & Johnson by 3.8% during the 4th quarter. Northeast Financial Consultants Inc now owns 42,256 shares of the company’s stock worth $7,229,000 after purchasing an additional 1,566 shares during the last quarter. Laraway Financial Inc acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $924,000. Finally, Forefront Analytics LLC lifted its stake in Johnson & Johnson by 3.5% during the 4th quarter. Forefront Analytics LLC now owns 1,919 shares of the company’s stock valued at $328,000 after acquiring an additional 64 shares during the period. Institutional investors own 68.78% of the company’s stock.
Several brokerages have commented on JNJ. Sanford C. Bernstein cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lifted their price objective for the company from $180.00 to $183.00 in a research note on Wednesday, March 16th. Raymond James boosted their target price on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 6th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Finally, Bank of America began coverage on shares of Johnson & Johnson in a research note on Wednesday, March 2nd. They issued a “neutral” rating for the company. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $187.86.
Shares of Johnson & Johnson stock traded down $1.56 during mid-day trading on Thursday, reaching $173.94. 6,873,945 shares of the stock traded hands, compared to its average volume of 7,914,567. The business has a 50-day moving average of $178.41 and a 200 day moving average of $170.70. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The stock has a market capitalization of $457.71 billion, a PE ratio of 23.49, a PEG ratio of 2.94 and a beta of 0.66. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, beating analysts’ consensus estimates of $2.60 by $0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The business had revenue of $23.43 billion during the quarter, compared to analysts’ expectations of $23.62 billion. During the same quarter in the prior year, the firm earned $2.59 earnings per share. The business’s revenue was up 5.0% compared to the same quarter last year. On average, equities research analysts expect that Johnson & Johnson will post 10.2 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th will be issued a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.60%. The ex-dividend date is Monday, May 23rd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.14%.
Johnson & Johnson Company Profile (Get Rating)
Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- The Institutional Tide Has Turned For Cisco Systems
- Don’t Bet On Cheaper Oil, Not Yet Anway
- Can Nvidia Bounce Back
- A Reversal In The S&P 500 Is Confirmed
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.